Vectalys will attend the ASGCT on May 4-7, 2016 in Washington, DC to introduce the next generation of non integrating lentiviral particle for gene and cell therapy applications.
We look forward to sharing with you our new non-integrative MS2-based lentiviral particles for mRNA delivery at the American Society of Gene and Cell Therapy (ASGCT 2016). This innovative particle is a safe and efficient opportunity for gene and cell therapy applications.
The details of the presentation are :
Session Date/Time: Friday May 6, 2016 6:00 PM - 8:00 PM
Session title: RNA Virus Vectors
Room: Exhibit Hall C & B South
Final abstract number: 538
Our staff on site :
Pascale Bouille, CEO of Vectalys,
If you would like to set up an appointment date and time prior to the annual meeting, please contact us at firstname.lastname@example.org or by phone +33 5 82 99 11 02.
Looking forward to seeing you there!
The Vectalys Team